Pleiotropic Effects and Safety of Sodium glucose co-transporter 2 inhibitor versus sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver - SGLT2 Inhibitor versus Sulfonylurea on Type 2 Diabetes with NAFLD

Kanazawa university hospital Department of Disease Control and Homeostasis0 个研究点目标入组 40 人开始时间: 2016年1月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Hepatic virus infections, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, haemochromatosis, antitrypsin deficiency, Wilsons disease, history of parenteral nutrition and use of drugs known to induce steatosis or hepatic injury caused by substance abuse and or the current or past consumption of more than 20 g of alcohol daily Hypersensitivity to or contraindication of glimepiride and tofogliflozin None type 2 diabetes Poorly controlled diabetes Repeated episodes of unexplained hypoglycemia Concomitant infection or planned surgery Poorly controlled hypertension Severe retinopathy Malignancy on an active therapeutic regimen or malignancy without complete remission or cure Severe health problems not suitable for the study Pregnant or lactating women Inability to participate in the study as assessed by the investigators.

发起方

Kanazawa university hospital Department of Disease Control and Homeostasis